Summary
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.8 per share a year ago.
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.55 per share a year ago.
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CervoMed Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $15 | $2.99 | -$12.01 | -80.07% |
 Richard Slavik Newbridge Financial Services Group Inc. | 3,000 | $23,700 | $8,565 | -$15,135 | -63.86% |
| MC mike Chen Byrne Asset Management LLC | 51,250 | $231,262.5 | $157,337.5 | -$73,925 | -31.97% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 5 | $20 | $13.95 | -$6.05 | -30.25% |
 Amir Har-El Savvy Advisors, Inc. | 25,922 | $209,709 | $72,322.38 | -$137,386.62 | -65.51% |
CervoMed Inc. (CRVO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CervoMed Inc. ever had a stock split?
CervoMed Inc. Profile
| Biotechnology Industry | Healthcare Sector | John J. Alam CEO | NASDAQ (CM) Exchange | 15713L109 CUSIP |
| US Country | 15 Employees | - Last Dividend | 17 Aug 2023 Last Split | 4 Jan 2016 IPO Date |
Overview
CervoMed Inc. is a pioneering biotechnology firm focused on addressing the growing needs in the management of age-related neurological disorders. Since its inception in 2010, the company has made significant strides in the field, dedicating its resources to the development and commercialization of cutting-edge treatments. Situated in Boston, Massachusetts, a hub of biotechnological advancement, CervoMed has been at the forefront of introducing innovative solutions designed to improve the lives of individuals suffering from debilitating neurological conditions.
Products and Services
- Neflamapimod:
This flagship drug candidate represents a major advancement in CervoMed's portfolio. Neflamapimod is an orally administered small molecule designed to penetrate the brain, targeting the treatment of various forms of dementia, including dementia with Lewy bodies (DLB), Alzheimer's disease, and frontotemporal dementia. Additionally, it is being explored as a potential therapy for aiding recovery from ischemic strokes. The versatility and breadth of application of neflamapimod underscore CervoMed's commitment to addressing a range of neurological disorders with a single, innovative solution.
- EIP200:
In the pipeline, EIP200 stands out as another significant endeavor by CervoMed to combat neurological diseases. Currently in preclinical trials, this novel compound is being developed specifically for its potential applications within the central nervous system (CNS). The development of EIP200 demonstrates CervoMed's dedication to expanding its suite of therapeutic options, reinforcing its mission to provide comprehensive care for individuals afflicted with CNS disorders.
